Dan is an associate in the Boston office and a member of the Intellectual Property practice group. He focuses his practice on domestic and foreign patent prosecution primarily in the area of biotechnology, including the fields of cellular and molecular biology, oncology, immunology, microbiology, genetic engineering, stem cells, antibody therapeutics, pharmaceuticals, biochemistry, and probiotics.
Dan regularly counsels a broad range of clients, from small biotech start-ups and universities to established pharmaceutical companies.
•Dan prepares and prosecutes U.S. and foreign patent applications with an emphasis in the biological sciences, including drafting applications and responding to Office Actions. Dan's experience also includes drafting patent validity and infringement opinions, freedom-to-operate opinions, and due diligence evaluations of patent portfolios.
•Dan was part of a team that conducted the intellectual property due diligence for the $40 million sale of a crucial client product to a major nutritional company.
Before Edwards Wildman
Prior to joining the firm, Dan was an associate at another international law firm based in Boston, Massachusetts, where he focused on intellectual property matters.
Dan conducted his doctoral research in molecular microbiology. His dissertation focused on characterizing the pathogenic cascade of Acanthamoeba keratitis, a sight-threatening infection of the ocular surface. He was also the recipient of a doctoral training fellowship awarded by UT Southwestern and a grant-in-aid of research from the National Academy of Sciences, awarded by Sigma Xi, the Scientific Research Society.
Dan has authored and presented scientific publications in the fields of immunology, microbiology, parasitology, and ophthalmology.
Besides Edwards Wildman
In his free time, Dan is an avid college sports fan and enjoys cycling, photography, spending time at the gym, and hanging out with family and friends.
Edwards Wildman Client Advisory - U.S. Patent and Trademark Office Issues Guidance in View of Prometheus and Myriad
March 2014 publication
Edwards Wildman Client Advisory: Supreme Court Invalidates Claims to Isolated DNA, but Upholds Patent Eligibility of cDNA in Myriad
June 2013 publication
Edwards Wildman's Daniel Clarke Joins Firm's Intellectual Property Practice, Reports the Boston Media
April 23, 2013